MOUTH DISSOLVING TABLETS OF LOSARTAN POTASSIUM: FORMULATION AND EVALUATION

Losartan potassium is an angiotention receptor antagonist, used in the management of hypertension. The objectiveof the proposed research work is to prepare and evaluate the mouth dissolving/disintegrating tablets (MDTs) of losartan Potassium, which avoid the first-pass metabolism, improved the dissolution rate and enhance the bioavailability. Mouth dissolving tablets (MDTs) were prepared by direct compression method by using combination of superdisintegrant like Ac-Di-Sol and Polyplasdone-xl (1%,2%,3%&4%) and evaluated for physico-chemical evaluation parameter such as hardness, friability, weight variation, drug content uniformity, water absorption ratio, wetting time, in-vitro and in-vivo disintegration time, in-vitro dissolution studies. The control tablet (without superdisintegrant) was formulated and evaluated. The twelve formulations, B1to B8 were formulated and among these formulations, B8 was optimized. The hardness, friability, weight variation and drug content were found to be within pharmacopeias limits. The water absorption ratio, wetting time, in-vitro and in-vivo disintegration time of optimized formulation, B8 was found to be 86.1%, 8secs, 18secs and 25secs respectively. The formulation, B8 was considered to best formulation, which released up to 99.21% in 2 minutes. The comparison of dissolution rate profile of marketed formulation of Losartan potassium (Losacar) tablet with best formulation, B8 was conducted. The result showed that the formulation, B8showed complete drug release within 2 minutes and marketed formulation showed complete drug release in 5 minutes. The stability study was also conducted the best formulation, B8 and it indicates that there was no significant change in any parameters. Hence the formulation A4 was considered to be highly stable.